banner2

Getting started
2-Chloro-4-Iodopyridine

2-Chloro-4-Iodopyridine - Manufacturers, Factory, Suppliers from China

2-Chloro-4-Iodopyridine, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

2-Chloro-4-Iodopyridine CAS 153034-86-7 — 2-Chloro-4-Iodopyridine CAS 153034-86-7 Purity >99.0% (GC) Factory Hot Sale
Read More

Z-HomoPhe-OH CAS 127862-89-9 Assay ≥98.0% (HPLC)

Z-Ser-OH CAS 1145-80-8 N-Cbz-L-Serine Assay ≥99.0% (HPLC)

Z-Hyp-OH CAS 13504-85-3 Purity ≥99.0% (HPLC)

N-Cbz-N-Methyl-L-Isoleucine CAS 42417-66-3 Purity ≥98.0% (HPLC)

D-2-Cyanophenylalanine CAS 263396-41-4 Assay ≥98.0% (HPLC)

D-3-Cyanophenylalanine CAS 263396-43-6 Assay ≥98.0% (HPLC)

banner4

Top Selling Products

Related Blog
Reviews

The 19th Beijing Conference and Exhibition on Instrumental Analysis (BCEIA 2021)-Shanghai Ruifu Chemical Co., Ltd. participated in the exhibition

The 19th Beijing Conference and Exhibition on Instrumental Analysis (BCEIA 2021) was held on September 27-29, 2021 at China International Exhibition Center (Tianzhu New Hall), Beijing. Adhering to...
The Third Conference on Boron Chemistry of Chinese Chemical Society，CCS-CBS-III

The Third Conference on Boron Chemistry of Chinese Chemical Society (CCS-CBS) will be held in Suzhou, Jiangsu Province from October 15 to 18, 2021. This conference will be hosted by Inorganic Chemi...
The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) -Shanghai Ruifu Chemical Co., Ltd. will attend with customers.

Shanghai Ruifu Chemical Co., Ltd. will attend the The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) with customers. The 87th China International ...
Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models This forum focuses on the interdisciplinary and cutting-edge technologies...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
Xi presents award to top scientists

President Xi Jinping, also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission, presents China’s top science award to a...

2022.09.25 09:46:01
2022.05.17 21:02:38
2022.05.12 17:11:35
2022.03.16 21:16:07
2022.01.26 20:27:25
2021.12.05 15:42:41

related search